Introduction
Genome editing, alternatively termed gene editing, presents a set of advanced technologies that capacitate scientists to meticulously modify an organism’s DNA. These modifications involve the addition, removal, or alteration of genetic material at specific locations within the genome, thus enabling a precise manipulation of genetic sequences. Amidst the plethora of gene editing methodologies, the CRISPR-Cas9 technique stands out, offering a combination of speed, affordability, accuracy, and efficiency that surpasses its counterparts. Building upon this foundation, base editing and prime editing have emerged as advanced iterations, enabling precise nucleotide conversions and targeted insertions or deletions without introducing double-stranded DNA breaks.Reference Testa and Musunuru 1
The potential of CRISPR-Cas9 as a gene-editing tool was first articulated in 2012. The acronym CRISPR stands for Clustered Regularly Interspaced Short Palindromic Repeats, a bacterial defense system that is programmable to target and edit specific stretches of genetic code. The CRISPR-Cas9 system, originally discovered in archaea and later in bacteria by Francisco Mojica,Reference Mojica 2 works by transcribing “spacer” sequences into short RNA sequences that guide the system to corresponding DNA sequences. This guidance allows the Cas9 enzyme to introduce targeted double-strand breaks or modulate gene expression, thereby effecting genetic modification. The CRISPR-Cas9 system is a highly efficient and customizable alternative to other gene editing tools (meganucleases, zinc finger nucleases and transcription activator-like effector nucleases — TALENs), primarily because it can be easily paired with tailor-made guide RNA sequences, enabling it to target multiple genes concurrently (the so-called “multiplexed CRISPR/Cas9 genome editing”).Reference Cao, Xiao and Yan 3
The chief characteristic of the CRISPR-Cas9 system is its ability to permanently modify genes within living cells and organisms. This attribute has significant implications for treating genetic diseases. It suggests the potential to correct mutations within the human genome, thus providing a novel solution to a raft of genetic conditions. Furthermore, the CRISPR-Cas9 system’s flexibility allows it to be used for a myriad of purposes beyond medicine, including but not limited to the following: engineering disease-resistant crops, which could significantly boost agricultural productivity and sustainability, creating animal models for research, thereby enhancing our understanding of disease mechanisms and potential treatments, and engineering bacteria for environmental purposes, such as cleaning up oil spills or reducing greenhouse gas emissions.Reference Ran 4
Genome editing, specifically with the utilization of the revolutionary CRISPR-Cas9 system, can indeed be applied not only to adult organisms but also to embryos, a technical aspect that promises groundbreaking advances in the field of genetics.Reference Ledford 5 Traditionally, genome editing was only possible in adult organisms where the edited genes could not be inherited by future generations. This was due to the fact that the modifications were made after the differentiation of somatic cells, which are not involved in reproduction. However, the advent of technologies like CRISPR-Cas9 has expanded the realm of genome editing to include embryos, thereby opening up the possibility of heritable genome editing. CRISPR-Cas9 has been successfully employed in the modification of the embryonic genome. The technique involves introducing the Cas9 protein and guide RNA into the embryo at the single-cell stage. The guide RNA directs the Cas9 to the targeted gene sequence, effectively facilitating precise gene editing.
This process allows for the correction or alteration of specific gene sequences within the embryonic genome, thus potentially rectifying genetic anomalies before the organism’s development. Moreover, the application of genome editing in embryos offers the potential advantage of systemic corrective changes as the single-cell embryo will eventually differentiate to form all the cells of the organism. Consequently, the edited gene would be present in each and every cell, ensuring a comprehensive rectification of the genetic anomaly. However, it should be underscored that while the technical feasibility of embryonic genome editing is well-established, the technique is still in its infancy and requires further research to refine its precision and eliminate off-target effects. Above all, the application of genome editing in embryos necessitates a robust scientific and regulatory framework to ensure its responsible use.Reference Papathanasiou 6
The use of CRISPR-Cas9 in clinical settings can be broadly categorized into two primary forms of gene therapy. Firstly, ex vivo approaches involve manipulating the genetics of cells outside the patient’s body and then reintroducing these altered cells back into the patient.Reference Li 7 Secondly, in vivo techniques entail modifying genes within the cells inside the patient’s body, necessitating advanced delivery mechanisms for the gene-editing tools. Further, the gene-editing process can be divided based on the cellular type targeted.Reference Behr 8 To illustrate, somatic cell editing, which impacts all non-reproductive cells and does not yield inheritable alterations, represents one category. On the other hand, germline editing, which involves interventions on embryos, zygotes or gametes leading to inheritable genetic changes, constitutes the other category. Legal restrictions vary worldwide for human germline editing, ranging from stringent regulations to outright prohibitions. Notably, all existing clinical trials that employ gene-editing are solely focused on somatic cells, including stem cells.
As with any potent technology, genome editing, and specifically the CRISPR-Cas9 technique, raise a host of ethical and safety concerns. Particularly contentious is the use of genome editing to alter human genomes, especially in germline cells and embryos. These concerns stem from the potential for unintended consequences, the risk of misuse for eugenic purposes, and the fundamental question of whether it is ethically acceptable to alter an individual’s genetic makeup without their consent. Consequently, germline cell and embryo genome editing are currently illegal in the United States and various other countries, reflecting the international community’s consensus on the need for stringent regulations to govern the use of these powerful tools.
Genome editing, and more specifically the CRISPR-Cas9 technique, heralds a new era in genetic engineering. Its potential applications are vast, promising solutions to longstanding challenges in medicine, agriculture, and environmental conservation. However, it also necessitates a careful ethical, legal, and societal dialogue to ensure its benefits are fully realized while minimizing potential harms.
Material and Methods
In this scoping review, we followed the methodological framework proposed by Arksey and O’Malley (2005)Reference Arksey and O’Malley 9 to explore the bioethical and medico-legal implications of genome editing in medicine. The review process comprised five main steps:
Step 1: Identifying the research question
We formulated the research question using the Population/Concept/Context (PCC) framework recommended by the Joanna Briggs InstituteReference Peters 10. The research question was: “What are the ethical, bioethical, and medico-legal implications of genome editing technologies (and in particular of the most used, CRISPR-Cas9) in medicine?”. The population was defined as patients and healthcare providers, the concept as ethical, bioethical, and medico-legal implications, and the context as the application of genome editing (and in particular CRISPR-Cas9) in medicine.
Step 2: Identifying relevant studies
We searched four electronic databases, namely PubMed, Scopus, Web of Science, and Ovid Medline, using specific keywords and MeSH terms related to the research question. The search strategy included the following terms: “genome editing,” “CRISPR-Cas9,” “ethics,” “bioethics,” “medico-legal,” “regulation,” and “law.” The search strings were tailored for each database, using appropriate Boolean operators and database-specific syntax. We narrowed down the research to the period between January 1, 2012, and September 30, 2024. We only considered articles in English. We did not set any restrictions regarding the type of articles, but as a source type, we have only considered ‘journals’, thus excluding books, conference proceedings, etc. The grey literature was not considered. In Table 1, the search strings used in the four databases are illustrated.
Search strings
Step 3: Selecting studies
We aimed to be more discerning than other existing reviews on the subject,Reference Joseph 11 focusing solely on articles broadly exploring the bioethical implications of genome editing. The selection process was conducted as follows. Initially, we subjected the initial library of 2905 articles retrieved from the 4 databases to preliminary scrutiny using the EndNote software. Through an automated software function, we eliminated duplicate articles and those evidently irrelevant to the review’s purpose, resulting in a pool of 1364 articles. These articles were then independently and blindly screened by the authors using the Rayyan tool (Rayyan is a web-based software tool designed to facilitate systematic reviews by aiding the process of screening and selecting studies), wherein inclusion or exclusion was based on the reading of the title and/or abstract. Following the Rayyan screening process, the remaining 172 articles underwent a more detailed examination, involving a thorough review of the full texts. A significant portion (123 articles) was eliminated as they discussed the bioethical implications of genome editing only marginally, thereby deeming them unsuitable for our review. A smaller section (39 articles) was excluded for various reasons, specifically: examination of a single bioethical aspect without a comprehensive overview, analysis of a single form of genome editing (e.g., germline), examination of the technique only in specific sectors (e.g., military), analysis of genome editing applications to treat individual diseases (e.g., hemophilia), predominantly philosophical or theological focus, and examination of a specific population or group’s opinion on genome editing technique. Thus, 10 articles remained, which were included in the review. Figure 1 presents a diagram illustrating the selection process stages.
The selection process of articles included in the review.
Step 4: Charting data
To gather the required data to address the review question, we utilized a data charting form with the help of the Excel software. We chose to pull out the subsequent data from the chosen individual articles:
-
1. Title
-
2. Year of publication
-
3. Geographical context (country where the author or authors work)
-
4. Article type
-
5. Main bioethical and medico-legal issues related to genome editing
The paper’s title swiftly ushered us towards the primary emphasis of the study. The publication year and the authors’ nationality were instrumental in contextualizing the article within its technological timeframe and geographical-cultural milieu. Identifying the article type was crucial for grasping the extent of the research. The key findings offered us insights into the final deductions made in the article.
Step 5: Collating, summarizing and reporting results
We reported the results of the review in a schematic form within Table 2. In the last column, the Scale for the Assessment of Narrative Review Articles (SANRA) score is reported. SANRAReference Baethge, Goldbeck‐Wood and Mertens 12 is a quality assessment tool specifically designed for narrative review articles. It is based on a six-point system that evaluates different parameters to ensure the quality and clarity of the information provided. The parameters include the definition of the research question or objective, the search strategy and data sources, the inclusion and exclusion criteria of primary studies, the data extraction methods, the scientific quality of the included studies, and the presentation of results. This system helps to ensure that review articles are scientifically sound, methodologically accurate, and provide a comprehensive summary of the existing literature on a specific topic. In the present study, we believed we could apply the SANRA score to articles identified as “perspective articles” or “original research” as they still have the structure and setup of a literature review. The overall quality was determined as poor (score 0–6), moderate (7–9), or excellent (10–12). The SANRA scores attributed represent the outcome of a quality analysis activity carried out by the authors of this review: it is therefore a subjective judgment that does not claim to indicate the actual and real quality of the articles under consideration.
Overview of articles included in the review
Discussion
As revealed by the literature review, genome editing, particularly through techniques such as CRISPR-Cas9, carries profound bioethical implications that extend into every stratum of society. These implications transcend the boundaries of science and delve into the realms of morality, human rights, societal norms, and equality.
Exacerbation of social inequalities is one of the most prominent implications. 23 Genome editing, if accessible only to the affluent, threatens to widen the socio-economic gap, creating a “genetic elite” with potential advantages in health, longevity, or even cognitive abilities. This could result in biological disparities that amplify existing social inequalities, further marginalizing disadvantaged groups. Non-CRISPR gene editing treatments cost between $450,000 and $2 million,Reference Sherkow 24 while treatments based on CRISPR technology cost up to $3.5 million (such as Hemgenix, for the treatment of hemophilia B),Reference Tanne 25 and are therefore unaffordable for most, particularly for marginalized communities, who face additional barriers such as living in areas with limited access to cutting-edge therapies and having less knowledge about them. For equitable application, systemic issues such as racially biased medical practices must be addressed. Furthermore, there is a significant underrepresentation of minorities in genomics and gene editing research, which needs to be addressed to mitigate health equity challenges.Reference Subica 26
The dependency upon “enhancement” applications is another issue. 27 If genome editing is used for non-therapeutic enhancements, such as improving physical appearance or intellectual capacity, it could lead to an unhealthy obsession with genetic perfection. This dependency could potentially redefine societal norms, placing unwarranted pressure on individuals to conform to these artificially established standards. As suggested by Nicholas Agar, it is important to distinguish between what is “morally wrong” and what is “morally problematic.”Reference Agar 28 During the early 1900s, there were undoubtedly morally reprehensible applications of eugenics (e.g., the forced sterilization of the mentally and physically disabled imposed in July 1933 by the Nazi regime), but that does not imply all eugenic applications (even today) are morally wrong. When we categorize eugenics as essentially “morally problematic,” it implies that we do not foresee moral progress shifting the issue into the realms of the unproblematically morally right or wrong. The decisions concerning the kind of future individuals we bring into existence are expected to remain philosophically challenging. 29 Pre-implantation genetic diagnosis (PGD) is a classic example of the application of eugenics that cannot be described as “morally wrong.” In PGD, multiple embryos are produced via in vitro fertilization. These embryos are then examined for genetic variations that may increase the likelihood of certain diseases that parents may wish to circumvent. Embryos devoid of such risk-associated genetic variations can then be implemented to commence a pregnancy. This procedure is accessible in a plethora of countries, and in the majority of these places, its application is confined to preventing severe genetic disorders. In current societies, there are no regulations mandating prospective parents with a high risk of transmitting genetic diseases to utilize PGD. The choice to have children without employing tests that can identify hereditary risks is respected. If parents at high risk of passing on severe genetic diseases were required to use PGD, the overall health of the population could potentially be improved to a greater extent. In essence, therefore, PGD is considered to be a purely medical instrument and is made available to parents in cases where they are at risk of transmitting a serious illness: its limits and areas of application are thus clearly determined, excluding the possibility that the technique may be used for purposes other than preventing the birth of a seriously ill person. A similar view could be extended to genome editing, which would then present significantly reduced bioethical criticisms.
A further critical point from a bioethical point of view is undoubtedly the question of safety. Off-target mutations are one of the primary safety concerns in genome editing. 30 They occur when the CRISPR-Cas9 system binds to and cuts DNA sequences that are similar, but not identical, to the intended target sequence, leading to unintended genetic modifications.Reference Fu 31 These unintended modifications can potentially disrupt normal gene function and lead to adverse health outcomes. Recent studies have reported a significant frequency of off-target mutations in both in vitro and in vivo models, highlighting the need for increased precision and accuracy in genome editing technologies.Reference Zhang 32 The potential for immunological dysregulation is another significant safety issue. 33 The immune system could potentially recognize the foreign Cas9 protein as a threat and mount an immune response, potentially leading to inflammation, cytotoxicity, and other adverse effects, and in severe cases, even death.Reference Crudele and Chamberlain 34 Moreover, there is a risk that the immune system could develop “immunological memory,” leading to a heightened immune response upon subsequent exposures to the Cas9 protein. Critical security issues highlighted highlight the need for rigorous ethical scrutiny, robust regulatory frameworks, and comprehensive public dialogue in the advancement of this technology. The goal should not just be to harness the power of genome editing, but to do so in a manner that respects human dignity, rights, and safety.
Another aspect of great importance in bioethical terms is the potential ecological and evolutionary risks associated with genome editing. 35 Genome editing, and especially germline genome editing, holds great promise in preventing life-threatening diseases. While the technology has been successfully applied in non-human animals, 36 the implications for human applications are far-reaching and controversial. Primarily, editing the germline means changes made will be inheritable, influencing not just a single individual but future generations.Reference Greely 37 This could unintentionally alter the course of human evolution, as it could lead to an imbalance in genetic diversity, and potentially, the emergence of new diseases. It could also introduce a new form of inequality, where only those with access to such technologies can ensure their offspring inherit “desirable” traits. Ecologically, the use of genome editing in non-human animals or plants could disrupt ecosystems. If genetically modified organisms (GMOs) were to outcompete or replace native species, this could lead to a loss of biodiversity. Genome editing might unintentionally alter the genetic diversity that underlies the survival of the human species.Reference Cavaliere 38 Furthermore, GMOs could have unpredictable interactions with other species in the ecosystem, potentially leading to unforeseen consequences. The provisions of the Convention on Biological Diversity (CBD) could intervene to prevent such a scenario.Reference Keiper and Atanassova 39 The Convention on Biological Diversity (CBD) is a multilateral treaty championed by the United Nations with three central objectives: the conservation of biodiversity, the sustainable use of its components, and the fair sharing of benefits from genetic resources. It was opened for signature in 1992 and came into force in 1993, with the United States being a notable exception as it has not ratified the treaty. The United States’ non-ratification of the CBD is largely attributed to domestic political concerns, including issues of national sovereignty and fears of potential economic repercussions. Despite this, the US continues to support the goals of the CBD indirectly, implementing biodiversity conservation policies at the national level and participating as an observer in international discussions. The absence of US ratification highlights a critical gap in the global governance of genetic technologies, potentially complicating the uniform application of safeguards against the risks posed by genome editing. The CBD has two supplementary agreements: the Cartagena Protocol on Biosafety, which regulates the movement of genetically modified organisms, and the Nagoya Protocol on Access to Genetic Resources and the Fair and Equitable Sharing of Benefits, which provides a legal framework for the fair and equitable sharing of benefits arising from the use of genetic resources. The Convention on Biological Diversity serves as the most progressive and comprehensive structure for controlling gene editing and preserving biodiversity amidst the increasing prevalence of CRISPR technology. The daunting task of this responsibility rests on its shoulders now and in the foreseeable future.Reference Grunewald 40
The existence of a connection between the human genome and human dignity, understood as the intrinsic worth and equal value of every human being regardless of genetic traits or modifications, is also at stake. 41 Genome editing, particularly if used for enhancements, could alter our understanding of what it means to be human.Reference Jasanoff and Hurlbut 42 This could jeopardize human dignity by reducing individuals to their genetic makeup. This potentiality evokes an image of a society where genetic “haves” and “have-nots” are sharply demarcated, undermining the intrinsic equality that underpins human dignity.Reference Bess 43 The prospect of artificially enhancing humans also raises the question of our relationship with nature, challenging the belief in the sanctity of the “natural” human form.Reference Harris 44 As genome editing continues to evolve, it is vital to engage in rigorous ethical and philosophical discourse to ensure that it is used in a manner that respects and upholds human dignity, rather than subverting it.Reference Caplan 45
The potential misuse of genome editing technologies is another concern. These technologies could be exploited for nefarious purposes, such as the creation of bioweapons or the production of “designed babies,” posing substantial risks to society. 46 Furthermore, the excessive broadening of the range of subjects that could benefit from genetic editing and the lack of means to assist them all underscores the need for careful prioritization and regulation. With limited resources, it is essential to ensure that genome editing technologies are used judiciously and for the benefit of all.
The inability of future generations to give consent to genome interventions is a significant ethical issue. Altering the germline genome affects future generations who cannot consent to these changes, potentially infringing upon their rights. 47 This perspective aligns with the precautionary principle, which advocates for a conservative approach in the face of uncertainty, especially when the potential risks are significant and essentially irreversible.Reference Ishii 48 Furthermore, Habermas argues that genetic interventions on future generations may compromise their autonomy, by predetermining certain aspects of their identity and capabilities.Reference Habermas 49 Relatedly, genome editing research may involve the collection and use of genetic information, raising concerns about genetic privacy. As more people’s genetic data is stored and analyzed, there is a risk that it could be misused, leading to discrimination, stigmatization, or other harms. Ensuring robust privacy protections and informed consent processes is essential to safeguard individuals’ rights and autonomy in the context of genome editing research.Reference Wan 50
Another key legal issue surrounding genome editing is the question of intellectual property rights. The development of CRISPR-Cas9 and other genome editing technologies has been accompanied by a complex web of patent disputes, licensing agreements, and other legal battles. Driven by the potential financial benefits, individual scientists and organizations alike were keen to stake their claim on the lucrative CRISPR-Cas9 technology. An early patent application was jointly filed in May 2012 by the University of California at Berkeley (on behalf of Doudna), the University of Vienna, and Charpentier, who was individually credited in line with University of Umeå’s regulations, where he was employed at the time.Reference Gostimskaya 51 However, in December 2012, Zhang and the Broad Institute also sought a patent, coinciding with the acceptance of Zhang’s paper on human cell editing for publication in Science. Zhang’s application was initially successful, securing a patent in April 2014, while Doudna’s submission was still under review. This led to a protracted dispute involving appeals and courtroom battles, creating a murky situation around CRISPR-Cas9 licensing. 52 By 2019, both parties held patents, leading to a split in the biotech industry with some companies licensing from Doudna’s team and others from Zhang’s. In February 2022, the US Patent and Trademark Office Appeal Board once again confirmed Zhang and the Broad Institute’s preeminence as the patent holders for CRISPR-Cas9 usage in human cells. This decision caused considerable dissatisfaction and financial difficulties for companies licensed by Doudna’s team. Despite this, Doudna and Charpentier prevailed in a similar European dispute and also hold significant patents for the technology in the UK, China, Japan, Australia, New Zealand, and Mexico.Reference Campbell 53 The ethical relevance of the patent issue lies in its significant implications for the accessibility and affordability of genome editing tools. These disputes also influence how the benefits arising from the use of these technologies are distributed, potentially exacerbating inequities in access to this transformative innovation.
The use of genome editing technologies in medical practice also raises complex liability and medico-legal issues. As with any medical intervention, there is a risk that genome editing procedures could result in unintended consequences, such as off-target mutations or dysregulation of the immune system as explained above. These risks raise questions about the legal responsibilities of healthcare providers, researchers, and other stakeholders in the event of adverse outcomes. In addition to concerns about potential physical harms, there are also questions about the psychological and emotional impacts of genome editing. For example, individuals who undergo genetic modification may experience feelings of guilt, shame, or stigmatization, particularly if their edited genes are passed on to future generations. Addressing these complex medicolegal issues will require the development of new legal frameworks and liability standards, as well as ongoing engagement with affected communities and stakeholders.
A further aspect of bioethical interest is the regulation of the use of genome editing. In 2015, the first International Summit on Human Gene Editing established guidelines for research in this field, concluding that thorough preclinical research was needed, approving clinical trials involving somatic cell editing, and banning germline editing until further notification. However, the second international summit held in 2018 took a different stance, recognizing the need to address germline editing as a global problem. In December 2018, the World Health Organization (WHO) set up a specific commission known as the WHO Expert Advisory Committee on Developing Global Standards for Governance and Oversight of Human Genome Editing. This Committee’s mission is to delve into the ethical, scientific, legal, and societal implications and create an appropriate framework for governing genome editing. On July 14, 2021, the Committee put forth a report split into two separate documents, namely “Human Genome Editing: Recommendations” 54 and “Human Genome Editing: A Framework for Governance.” 55 The committee also published a position paper on both documents. These writings, collectively known as the WHO Report on Human Genome Editing, serve as a companion to an earlier report issued by the International Commission on the Clinical Use of Human Germline Genome Editing. This earlier report was a collaborative effort of the National Academy of Medicine, the National Academy of Sciences, and the Royal Society, released in September 2020. 56 The documents from the WHO committee provide a conceptual framework for managing issues related to human genome editing, including fair access and distribution of benefits, risk assessment, regulation, and surveillance. The framework underscores the importance of international cooperation and shared norms to address the global challenges posed by human genome editing, while also promoting responsible innovation and adherence to ethical and social standards. While the documents themselves do not enact laws or regulations, they significantly influence the development of such regulations at both the national and international levels. Along with regulations, the implementation of genome editing in medical practice will also necessitate the establishment of robust oversight and monitoring systems. This will involve the development of guidelines, standards, and best practices for the responsible use of genome editing technologies, as well as mechanisms for enforcing compliance with these standards. Effective oversight will require collaboration between diverse stakeholders, including researchers, healthcare providers, regulatory bodies, and patient communities. This will help to ensure that genome editing is used in a manner that respects the rights and autonomy of individuals, as well as the broader social, ethical, and legal considerations surrounding the technology.
Finally, public engagement and education will be critical in addressing the medicolegal challenges associated with genome editing. As the technology moves closer to clinical application, it is essential that the public is informed about the potential benefits, risks, and ethical implications of genome editing. This will involve the development of targeted communication strategies, as well as efforts to promote dialogue and deliberation among diverse stakeholders. By fostering a well-informed and inclusive conversation about genome editing, it will be possible to ensure that the technology is used in a manner that reflects societal values and priorities.Reference Conley 57
It is important to reflect on the findings of this scoping review and the key bioethical and medicolegal implications of gene therapy (GT), which, unlike gene editing, aims to introduce or replace faulty genes rather than directly modify the DNA sequence. Gene therapy, being an older and more established technology, has a more extensive body of literature addressing its ethical and legal implications. The ethical discussions surrounding GT have predominantly focused on medical applications, such as treating genetic disorders and rare diseases. For instance, a scoping review by Kimberly et al. (2023) emphasizes the ethical challenges in pediatric gene therapy trials.Reference Kimberly 58 In comparison, gene editing (GE) literature encompasses a broader spectrum, including nonmedical applications like human enhancement and agricultural modifications. This expansion raises additional ethical questions about the appropriate boundaries of GE use. Furthermore, certain ethical issues are more pronounced in GE literature. The potential for germline editing introduces concerns about heritable changes and long-term societal impacts, topics less prevalent in GT discussions. Additionally, the relative ease and affordability of GE technologies have sparked debates about equitable access and the risk of unregulated use, as highlighted by the Nuffield Council on Bioethics (2018). 59
Ultimately, our review identified several gaps in the current GE literature. One notable gap is the limited exploration of the long-term societal and ethical consequences of germline editing, an area that demands more comprehensive and forward-looking studies. Additionally, the rapid progression of GE technologies has significantly outpaced the establishment of robust regulatory frameworks, creating an urgent need for further investigation into governance models that can keep pace with technological advancements. Finally, there is a scarcity of research focused on public engagement and education strategies.
Conclusion
Genome editing, particularly through the use of CRISPR-Cas9, has the potential to revolutionize medicine and other fields. However, the technology raises a host of complex bioethical, legal, and regulatory issues that must be carefully considered and addressed. By engaging in an ongoing, informed, and inclusive dialogue about these challenges, it will be possible to foster responsible research and innovation in the field of genome editing, ultimately realizing its significant possibilities while safeguarding the rights, wellbeing, and autonomy of individuals and communities.
Looking ahead, several critical ethical and medicolegal challenges remain unresolved. Among these, the question of equitable access to genome editing technologies looms large, as disparities in access could exacerbate existing social inequalities and create a “genetic divide.” Additionally, the lack of comprehensive regulatory frameworks, particularly for germline editing, poses significant risks, including the potential misuse of the technology for non-therapeutic enhancements or unregulated applications. The ethical implications of heritable genetic modifications also demand careful consideration, as they raise concerns about consent from future generations and the possibility of unintended long-term consequences for the human genome. Lastly, fostering public understanding and engagement remains a pressing challenge, as societal acceptance and informed decision-making are vital to the responsible implementation of genome editing technologies.
Study Limitations
This study, while comprehensive in its scope, does bear several limitations that must be acknowledged. Firstly, the omission of grey literature may have led to an underrepresentation of certain perspectives or findings that are not present in the peer-reviewed literature. Secondly, the restriction to only English language articles potentially excludes valuable insights from non-English speaking regions, thus limiting the cultural diversity of the ethical considerations. Lastly, the databases utilized for this review did not include publications of a humanistic nature which could have proffered useful elements for the thematic analysis of genome editing’s ethical implications. These limitations suggest areas for future research to further deepen our understanding of this complex issue. It should also be noted that this scoping review was not registered.
